Russell Investments Group Ltd. Has $122.09 Million Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Russell Investments Group Ltd. lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 500,864 shares of the medical instruments supplier’s stock after buying an additional 26,454 shares during the period. Russell Investments Group Ltd. owned about 0.17% of Becton, Dickinson and Company worth $122,086,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Jeppson Wealth Management LLC raised its stake in Becton, Dickinson and Company by 4.0% during the third quarter. Jeppson Wealth Management LLC now owns 1,028 shares of the medical instruments supplier’s stock worth $266,000 after buying an additional 40 shares during the last quarter. CX Institutional raised its stake in Becton, Dickinson and Company by 3.0% during the third quarter. CX Institutional now owns 1,491 shares of the medical instruments supplier’s stock worth $385,000 after buying an additional 43 shares during the last quarter. U.S. Capital Wealth Advisors LLC raised its stake in Becton, Dickinson and Company by 3.4% during the third quarter. U.S. Capital Wealth Advisors LLC now owns 1,310 shares of the medical instruments supplier’s stock worth $339,000 after buying an additional 43 shares during the last quarter. Value Partners Investments Inc. raised its stake in Becton, Dickinson and Company by 5.2% during the third quarter. Value Partners Investments Inc. now owns 867 shares of the medical instruments supplier’s stock worth $225,000 after buying an additional 43 shares during the last quarter. Finally, Atlas Private Wealth Management raised its stake in Becton, Dickinson and Company by 2.9% during the third quarter. Atlas Private Wealth Management now owns 1,587 shares of the medical instruments supplier’s stock worth $410,000 after buying an additional 45 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Up 0.5 %

BDX traded up $1.07 during midday trading on Friday, hitting $231.55. The company had a trading volume of 738,154 shares, compared to its average volume of 1,001,849. Becton, Dickinson and Company has a 52 week low of $229.40 and a 52 week high of $287.32. The company has a quick ratio of 0.64, a current ratio of 1.08 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $66.90 billion, a price-to-earnings ratio of 54.87, a PEG ratio of 1.91 and a beta of 0.43. The stock’s 50 day moving average price is $239.24 and its 200 day moving average price is $241.24.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, beating the consensus estimate of $2.39 by $0.29. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.73 billion. During the same period in the previous year, the firm posted $2.98 earnings per share. The business’s revenue was up 2.6% compared to the same quarter last year. On average, research analysts anticipate that Becton, Dickinson and Company will post 12.94 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BDX has been the subject of a number of analyst reports. Barclays lifted their target price on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Raymond James lifted their target price on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and a consensus target price of $280.00.

Insider Transactions at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the sale, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at $542,348.04. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.31% of the stock is currently owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.